Dr Audrey Kong presents at the ADS President’s Young Investigator Award
Congratulations to Dr Yee Wen Kong on her selected presentation at the IDF, ADC and Metabolic Diseases Congress in Melbourne. Dr Kong was invited to share her research findings from PARTNER study at the Australian Diabetes Society President’s Young Investigator Award. Her research explored SGLT2 inhibitors, a type of diabetes medication that helps lower blood sugar by helping the kidneys remove more glucose through urine, in adults with type 1 diabetes. In a study of 65 adults, the SGLT2 inhibitor Dapagliflozin helped people spend more time in their target blood sugar range, while also reducing insulin requirements and body weight, with no cases of diabetic ketoacidosis (DKA) reported during the study. These encouraging findings highlight that this therapy may be suitable in people with type 1 diabetes when there is careful ketone monitoring and education.
Dr Audrey Kong presents at the ADS President’s Young Investigator Award
Congratulations to Dr Yee Wen Kong on her selected presentation at the IDF, ADC and Metabolic Diseases Congress in Melbourne. Dr Kong was invited to share her research findings from PARTNER study at the Australian Diabetes Society President’s Young Investigator Award. Her research explored SGLT2 inhibitors, a type of diabetes medication that helps lower blood sugar by helping the kidneys remove more glucose through urine, in adults with type 1 diabetes. In a study of 65 adults, the SGLT2 inhibitor Dapagliflozin helped people spend more time in their target blood sugar range, while also reducing insulin requirements and body weight, with no cases of diabetic ketoacidosis (DKA) reported during the study. These encouraging findings highlight that this therapy may be suitable in people with type 1 diabetes when there is careful ketone monitoring and education.